Efficacy and safety of hydroxychloroquine for treatment of mild SARS-CoV-2 infection and prevention of COVID-19 severity in pregnant and postpartum women: A randomized, double-blind, placebo-controlled trial.

"CONFLICT OF INTEREST STATEMENT The authors have stated explicitly that there are no conflicts of interest in connection with this article."

"FUNDING INFORMATION This work was supported by the Instituto de Salud Carlos III from the Spanish Ministry of Science and Innovation extraordinary competitive peer‐review research call on SARS‐COV‐2 and COVID‐19. Project code: 286 (approved on April 17, 2020; grant holder: Clara Menendez)."

"Material and methods: A randomized, double‐blind, placebo‐controlled clinical trial was conducted in eight teaching hospitals in Spain to evaluate the safety and efficacy of HCQ in reducing viral shedding and preventing COVID‐19 progression. Pregnant and postpartum women with a positive SARS‐CoV‐2 PCR (with or without mild COVID‐19 signs/symptoms) and a normal electrocardiogram were randomized to receive either HCQ orally (400 mg/day for 3 days and 200 mg/day for 11 days) or placebo. PCR and electrocardiogram were repeated at day 21 after treatment start. Enrollment was stopped before reaching the target sample due to low recruitment rate. Trial registration EudraCT #: 2020‐001587‐29, on April 2, 2020. Clinical trials.gov # NCT04410562, registered on June 1, 2020."